Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1363348 | Bioorganic & Medicinal Chemistry Letters | 2010 | 4 Pages |
Abstract
A series of N1-alkyl pyrimidinediones were designed, synthesized and evaluated as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Our efforts identified compound 10b, which represents the lead compound in this series with pharmacokinetics and antiviral potency that may support once-daily dosing.
Graphical abstractEvaluation of a series of N1-alkyl pyrimidinediones as HIV-1 non-nucleoside reverse transcriptase inhibitors identified compound 10b, which represents the lead compound with pharmacokinetics and antiviral potency that may support once-daily dosing.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Michael L. Mitchell, Jong Chan Son, Hongyan Guo, Yun-A Im, Eun Jung Cho, Jianhong Wang, Jaclyn Hayes, Michael Wang, Amber Paul, Eric B. Lansdon, James M. Chen, Doris Graupe, Gerry Rhodes, Gong-Xin He, Romas Geleziunas, Lianhong Xu, Choung U. Kim,